GLP-1 Medications Explained: Uses, Benefits, Side Effects, and How They Work

GLP-1 medications have changed the conversation around type 2 diabetes, obesity, and weight management. Medicines such as semaglutide, liraglutide, and tirzepatide are increasingly discussed not simply as drugs that lower blood glucose, but as therapies that can influence appetite, food intake, body weight, and several cardiometabolic risk factors. Their popularity can sometimes make them sound like simple “weight-loss injections,” but their pharmacology is much more interesting than that description suggests. These medicines work by interacting with hormone pathways involved in glucose regulation and appetite, and their effects can extend beyond the number shown on a weighing scale. Current clinical evidence supports important benefits for selected patients, while also showing that gastrointestinal adverse effects and other safety considerations need to be taken seriously. The National Instituteof Diabetes and Digestive and Kidney Diseases explains that GLP-1 receptor agonists can lower blood glucose, reduce hunger, and help some people lose weight, while they remain prescription medicines that should be incorporated into an appropriate treatment plan rather than used casually.

What Are GLP-1 Medications?

GLP-1 medications are drugs that imitate or activate the effects of glucagon-like peptide-1, a hormone involved in the body's response to food. Naturally occurring GLP-1 is an incretin hormone, meaning it participates in the regulation of insulin secretion after meals. Pharmaceutical GLP-1 receptor agonists are designed to produce longer-lasting effects than the body's naturally occurring hormone, allowing them to be used therapeutically.

Depending on the specific medicine, these effects can include glucose-dependent stimulation of insulin secretion, suppression of glucagon under appropriate conditions, slower gastric emptying, and reduced appetite. This combination helps explain why the medicines can influence both blood glucose and body weight.

 Importantly, not every medicine commonly called a “GLP-1” has exactly the same pharmacology; tirzepatide, for example, activates both GIP and GLP-1 receptors and is therefore more accurately described as a dual GIP/GLP-1 receptor agonist. NIDDK identifies GLP-1 receptor agonists as injectable diabetes medicines that may also reduce hunger and support weight loss, while certain products and doses have separate indications for chronic weight management.

Understanding the GLP-1 Hormone

To understand these medicines, imagine GLP-1 as one part of the body's communication system between the digestive tract, pancreas, brain, and other tissues. After food enters the digestive system, incretin hormones help coordinate the metabolic response to that meal. GLP-1 signaling contributes to insulin release when blood glucose is elevated and also influences appetite and the rate at which food leaves the stomach. Pharmaceutical GLP-1 receptor agonists take advantage of this pathway by activating the GLP-1 receptor for considerably longer than natural GLP-1 would remain active. That extended action can make a person feel full sooner or remain full longer, while also improving glucose regulation. The result is not simply one isolated effect; it is a coordinated change in several physiological signals involved in eating and metabolism. NIDDK describes semaglutide and related medicines as acting on GLP-1 receptors in the intestine and brain, helping lower blood sugar, slow digestion, reduce hunger and cravings, and promote a feeling of fullness.

How Do GLP-1 Medications Work?

The easiest way to understand how GLP-1 medications work is to think about their effects at several different points in the body rather than searching for a single mechanism. In the pancreas, GLP-1 receptor stimulation can increase insulin secretion in a glucose-dependent manner, helping the body respond to elevated blood glucose after eating. At the same time, GLP-1 signaling can reduce inappropriate glucagon activity, which can contribute to lower glucose production by the liver. In the gastrointestinal tract, these medicines can slow gastric emptying, meaning food may move more slowly from the stomach into the intestine, which can influence post-meal glucose levels and fullness. In the central nervous system, GLP-1 signaling affects appetite-regulating pathways and can decrease hunger and food intake. This is why patients often describe feeling satisfied after smaller meals. The combined physiological effect can improve glycemic control and support weight reduction, although the magnitude of benefit differs from person to person and depends on the specific medicine, dose, indication, adherence, diet, physical activity, and underlying health conditions.

Effects on Blood Sugar, Appetite, and Digestion

Three effects are particularly important when explaining GLP-1 therapy: glucose regulation, appetite control, and gastrointestinal activity. When blood glucose rises, GLP-1 receptor agonists can enhance insulin secretion in a glucose-dependent manner, which is one reason they can be useful in type 2 diabetes. Their effect on appetite is equally important for weight management because they act on brain pathways involved in hunger and food intake, making it easier for some patients to consume fewer calories without experiencing the same level of hunger. The gastrointestinal effect can contribute to satiety by slowing gastric emptying, although this same mechanism is also connected with common adverse effects such as nausea, vomiting, fullness, constipation, or diarrhea. The overall experience can therefore be quite different from taking a conventional tablet that simply lowers glucose. It is more like adjusting several interconnected metabolic signals at once. NIDDK notes that GLP-1 medicines may make people feel less hungry and help with weight loss, while weight-management medicines generally work best when combined with healthy eating and physical activity rather than being treated as replacements for those measures.

Common GLP-1 Medications

Several medicines fall into the GLP-1-related treatment landscape, but their approved uses, doses, formulations, and schedules are not interchangeable.

Semaglutide is available in different products and strengths, including products used for type 2 diabetes and a higher-dose formulation used for chronic weight management.

Liraglutide is another GLP-1 receptor agonist that has been used in diabetes and, at a different dose, weight management.

Tirzepatide is different because it activates both GIP and GLP-1 receptors and is approved for type 2 diabetes under one brand and for chronic weight management under another, with additional indications in the United States.

NIDDK lists semaglutide and liraglutide among GLP-1 medicines used in diabetes and identifies tirzepatide as a dual GIP/GLP-1 medicine used for diabetes and weight management. The important clinical lesson is that a brand name should never be used as a substitute for understanding the active ingredient, indication, strength, and prescribing instructions.

Semaglutide

Semaglutide is one of the best-known GLP-1 receptor agonists and is available in both injectable and oral formulations for different indications. In the United States, semaglutide is marketed under different brand names depending on the formulation and approved use, including Wegovy for chronic weight management and Ozempic and Rybelsus for type 2 diabetes. The medicines are not simply different labels for identical prescribing situations because their approved indications, doses, formulations, and instructions differ. Semaglutide has attracted substantial attention because clinical trials demonstrated significant weight reduction in people with obesity and because cardiovascular outcome data have shown benefit in a specific population with established cardiovascular disease and overweight or obesity without diabetes. In the SELECT trial, 17,604 participants were randomized to weekly semaglutide 2.4 mg or placebo, and the primary cardiovascular endpoint occurred in 6.5% of the semaglutide group compared with 8.0% of the placebo group during the trial. These findings contributed to the FDA's 2024 approval of an indication for Wegovy to reduce cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and overweight or obesity.

Liraglutide

Liraglutide is another GLP-1 receptor agonist, but unlike once-weekly semaglutide, it has historically been administered as a daily injection. Different doses and brand names are associated with different therapeutic indications, so patients should not assume that the diabetes and weight-management products can be substituted for each other without medical guidance. Liraglutide works through the GLP-1 receptor and can improve glycemic control while reducing appetite and food intake. Its role in weight management helped establish the broader concept that incretin-based medicines could be used not only for diabetes but also as pharmacological treatments for obesity. NIDDK identifies liraglutide as a prescription medicine used for weight management and explains that the lower-dose formulation marketed under another name is used for type 2 diabetes. This distinction matters because patients sometimes see several brand names online and assume that all products containing the same active ingredient have identical dosing instructions. They do not. The correct formulation, dose, indication, and administration schedule should come from the prescribing information and the patient's healthcare professional.

Tirzepatide and Dual GIP/GLP-1 Action

Tirzepatide deserves special attention because it is not technically a pure GLP-1 receptor agonist. It activates both the glucose-dependent insulinotropic polypeptide, or GIP, receptor and the GLP-1 receptor, which is why it is commonly described as a dual GIP/GLP-1 receptor agonist. Its effects include reduced appetite and food intake, improved glucose regulation, and substantial weight reduction in appropriate patients. In the SURMOUNT-1 trial, adults with obesity or overweight plus a weight-related complication, without diabetes, received once-weekly tirzepatide or placebo for 72 weeks; substantial and sustained reductions in body weight were observed, and gastrointestinal adverse events were among the most common side effects. Longer-term data published from the same research program also found markedly lower progression to type 2 diabetes among participants with obesity and prediabetes who received tirzepatide compared with placebo over the studied period. In the United States, tirzepatide is also approved as Zepbound for adults with obesity and moderate-to-severe obstructive sleep apnea associated with obesity, alongside diet and increased physical activity.

What Are GLP-1 Medications Used For?

The uses of GLP-1-related medicines have expanded considerably, but the exact indication depends on the specific active ingredient, formulation, dose, and regulatory approval. Type 2 diabetes remains an important indication because these medicines can lower blood glucose while offering the additional advantage of weight reduction for many patients. Certain products and doses are also approved for chronic weight management in people who meet medical criteria related to obesity or overweight with weight-related health problems. Some medicines have demonstrated cardiovascular benefits in particular patient populations, and research continues to explore additional applications involving metabolic and cardiometabolic disease. For example, current diabetes guidance discussed by NIDDK includes GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists among treatment considerations for people with type 2 diabetes, obesity, and certain complications. This does not mean that every GLP-1 medicine is automatically appropriate for every condition. A medication should be selected according to the patient's diagnosis, treatment goals, contraindications, other medicines, kidney and liver considerations, tolerability, and the indication for which the product has been approved.

GLP-1 Medications for Type 2 Diabetes

For people with type 2 diabetes, GLP-1 receptor agonists can be valuable because they address glucose regulation through mechanisms that are closely connected to normal post-meal physiology. They can improve blood glucose control while often helping with weight loss, which may be particularly useful when type 2 diabetes occurs alongside overweight or obesity. NIDDK explains that GLP-1 medicines can lower blood glucose and may make people less hungry, while also emphasizing that they are not substitutes for insulin when insulin is required. Another important characteristic is that GLP-1 receptor agonists stimulate insulin secretion in response to elevated glucose rather than simply forcing insulin secretion regardless of glucose level, although hypoglycemia can still occur when these medicines are combined with other glucose-lowering treatments. The choice of therapy is therefore individualized rather than based solely on the patient's HbA1c. Cardiovascular disease, kidney disease, obesity, hypoglycemia risk, gastrointestinal tolerability, cost, route of administration, and other patient-specific factors can influence the treatment decision. For patients already taking multiple diabetes medicines, medication reconciliation is particularly important because adding a GLP-1 medicine may require adjustment of other therapies.

GLP-1 Medications for Weight Management

The weight-management effect of GLP-1-related medicines is one of the main reasons they have attracted enormous public attention. These medicines can reduce appetite and food intake while increasing feelings of fullness, which may create a sustained calorie deficit without relying entirely on willpower. NIDDK states that prescription weight-management medications can help eligible adults lose additional weight when combined with lifestyle interventions and notes that weight-management medication may be considered for adults with a BMI of at least 30, or at least 27 with a weight-related health problem, depending on clinical circumstances. The magnitude of weight loss varies substantially by medication and individual, and the results seen in clinical trials should not be treated as a guaranteed personal outcome. In the SURMOUNT-1 study, tirzepatide produced substantial weight reduction over 72 weeks, while semaglutide has also demonstrated substantial weight loss in obesity trials. Importantly, these medicines are not simply cosmetic treatments; medically significant weight reduction can influence blood pressure, glucose regulation, lipid-related risk, sleep apnea, mobility, and other obesity-related conditions in appropriate patients.

Cardiovascular Benefits of GLP-1 Therapy

Some GLP-1-related therapies have demonstrated cardiovascular benefits, but those benefits should always be discussed in the context of the population and trial in which they were established. The SELECT trial is an important example because it studied adults aged 45 years or older who had established cardiovascular disease, a BMI of at least 27, and no history of diabetes. Participants received weekly semaglutide 2.4 mg or placebo, and the primary composite outcome included cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. During a mean follow-up of approximately 39.8 months, the primary endpoint occurred in 6.5% of people assigned to semaglutide compared with 8.0% assigned to placebo, corresponding to a hazard ratio of 0.80. The FDA subsequently approved a cardiovascular risk-reduction indication for Wegovy in adults with cardiovascular disease and overweight or obesity. These results are clinically important, but they should not be generalized to every GLP-1 medicine, every patient, or every cardiovascular condition. Cardiovascular outcomes should therefore be interpreted according to the specific drug, dose, patient population, and indication supported by evidence.

Potential Benefits for Kidney and Metabolic Health

GLP-1-related medicines are also being studied and used within broader cardiometabolic care, particularly when type 2 diabetes and obesity coexist with other chronic conditions. NIDDK notes that newer therapies, including GLP-1 receptor agonists and SGLT2 inhibitors, can be relevant to people dealing with combinations of obesity, type 2 diabetes, heart disease, and kidney disease. The reason this matters is that metabolic diseases rarely occur in isolation. A person with type 2 diabetes may simultaneously have hypertension, obesity, cardiovascular disease, chronic kidney disease, fatty liver disease, or sleep apnea, so a medication that addresses more than one risk factor can become an important part of an integrated treatment plan. NIDDK's discussion of the 2025 diabetes standards also describes recommendations involving GLP-1 receptor agonists for certain people with type 2 diabetes and chronic kidney disease and treatment considerations for people with diabetes, obesity, and metabolic-associated fatty liver disease. These developments do not mean that GLP-1 drugs independently cure kidney or liver disease. Instead, they illustrate how incretin-based therapies are increasingly considered within a broader strategy for managing interconnected metabolic conditions.

Common Side Effects

The most frequently reported adverse effects of GLP-1-related medicines involve the gastrointestinal system. Patients may experience nausea, vomiting, diarrhea, constipation, abdominal discomfort, bloating, decreased appetite, or a feeling of fullness after relatively small meals. These effects can be particularly noticeable when treatment begins or when the dose is increased, which is why clinicians commonly use gradual dose escalation for medicines that require titration. In the SURMOUNT-1 tirzepatide trial, gastrointestinal adverse events were the most common and were generally mild to moderate, particularly during dose escalation. The FDA has also reported nausea, vomiting, abdominal pain, diarrhea, and constipation among adverse events associated with dosing problems involving compounded semaglutide and tirzepatide. Not everyone experiences these symptoms to the same degree, and some people find that they improve as their body adjusts to treatment. However, severe or persistent vomiting, inability to maintain hydration, severe abdominal pain, or other concerning symptoms should not simply be dismissed as a normal medication effect and may require prompt medical assessment.

Serious Side Effects and Safety Warnings

Although many adverse effects are gastrointestinal and manageable, GLP-1-related medicines have important warnings and precautions that should be reviewed before treatment begins. The exact warnings vary by product, so the prescribing information for the individual medicine should be used rather than assuming that all GLP-1 drugs have identical safety profiles. Patients should seek medical advice for severe or persistent abdominal pain, repeated vomiting, dehydration, symptoms suggesting gallbladder disease, or other significant changes after starting treatment. Hypoglycemia is more likely when GLP-1 therapy is combined with insulin or insulin secretagogues rather than when the medicine is used alone, making medication review important. Certain products also carry warnings concerning a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and NIDDK specifically lists these restrictions for semaglutide and liraglutide weight-management products and tirzepatide. The FDA has also received reports involving serious adverse events from dosing errors with compounded semaglutide, including severe gastrointestinal symptoms, dehydration, acute pancreatitis, and gallstones. Safety decisions should therefore be individualized rather than based on social-media claims that these medicines are either completely harmless or inherently dangerous.

Who Should Avoid or Use Caution With GLP-1 Medications?

Whether someone should use a GLP-1 medicine depends on medical history, current medications, treatment indication, and the specific product. A person with a personal or family history of medullary thyroid carcinoma or MEN2 may be advised not to use certain products because of their labeled contraindications. People with significant gastrointestinal problems, previous pancreatitis, gallbladder disease, diabetic complications, or other relevant conditions may require additional evaluation and monitoring depending on the medicine being considered. Pregnancy and plans for pregnancy also require careful discussion because weight-loss medications are not intended simply for cosmetic weight reduction during pregnancy. Another practical issue is the patient's ability to follow the dosing schedule correctly, particularly with injectable medicines or compounded products where concentration and measurement can create confusion. NIDDK emphasizes that weight-management medications are not appropriate for everyone with a high BMI and should be used together with healthy eating and physical activity when prescribed. Before starting treatment, patients should provide their healthcare professional with a complete medication list, medical history, allergy information, and relevant family history rather than relying on an online eligibility quiz.

GLP-1 Medications and Hypoglycemia

One common misunderstanding is that every GLP-1 medicine automatically causes frequent low blood sugar. The actual risk depends heavily on what the GLP-1 medicine is being combined with and on the patient's overall diabetes treatment plan. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner, which helps explain why they generally have a lower intrinsic hypoglycemia risk than therapies that increase insulin independently of glucose concentration. However, the risk can rise when a GLP-1 medicine is used alongside insulin or certain insulin secretagogues such as sulfonylureas. NIDDK specifically notes that some diabetes medicines can cause hypoglycemia and explains that GLP-1 medicines are not substitutes for insulin. Symptoms of hypoglycemia can include sweating, shakiness, hunger, dizziness, confusion, weakness, palpitations, and, in severe cases, loss of consciousness. Patients using combination therapy should therefore understand their glucose targets, recognize symptoms, monitor glucose when instructed, and know when to contact their healthcare team about medication adjustments.

How GLP-1 Medicines Are Taken

Administration depends on the specific drug. Some GLP-1 receptor agonists are once-daily injections, while others are once-weekly injections, and semaglutide is also available as an oral tablet for a particular diabetes indication. FDA information identifies Wegovy as a once-weekly injectable semaglutide product, Ozempic as a once-weekly injectable semaglutide product, and Rybelsus as an oral daily semaglutide tablet. Tirzepatide is also administered once weekly for its approved indications. The dose is often increased gradually for injectable medicines used for weight management or diabetes to improve tolerability, although the exact titration schedule depends on the product and indication. Patients should never independently accelerate dose increases because they want faster weight loss. The FDA has specifically reported dosing errors with compounded injectable semaglutide involving confusion between milligrams, milliliters, and “units,” with some errors resulting in patients receiving several times the intended dose. Correct administration therefore matters just as much as choosing the correct medicine.

GLP-1 Medications vs. Insulin

GLP-1 medicines and insulin are not interchangeable therapies, even though both can be used in diabetes management. Insulin directly supplies the hormone needed to move glucose from the bloodstream into cells and is essential for people with type 1 diabetes and for some people with advanced type 2 diabetes. GLP-1 receptor agonists, by contrast, work through incretin signaling and are primarily used in type 2 diabetes and other approved indications. They can improve glucose control without simply replacing endogenous insulin, and they often provide the additional benefit of reduced appetite and weight loss. NIDDK explicitly states that GLP-1 medicines are not substitutes for insulin. A patient with type 2 diabetes may receive both therapies when clinically appropriate, but the combination requires careful management because glucose levels can fall too low if treatment is not adjusted appropriately. The practical message is simple: a GLP-1 medicine should not be started, stopped, or substituted for insulin based on a social-media recommendation or a general statement that “GLP-1s are better.”

GLP-1 Medications vs. Other Weight-Loss Medicines

GLP-1-related medicines differ from many traditional weight-management medications because they influence hormonal pathways that regulate appetite, food intake, glucose metabolism, and digestion. Some older or alternative weight-management medicines act primarily through the central nervous system, reduce fat absorption, or influence other appetite-related pathways. GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists have become prominent because clinical trials have demonstrated substantial weight reduction for some patients. NIDDK reports that prescription weight-management medicines, when combined with lifestyle interventions, can produce additional weight loss compared with lifestyle intervention alone, although the amount varies by drug and individual. Tirzepatide's SURMOUNT-1 trial demonstrated substantial sustained weight reduction over 72 weeks, while semaglutide has produced substantial weight loss in clinical studies of obesity. Comparing medications should therefore involve more than asking which one causes the largest average weight change. Safety, contraindications, comorbidities, route of administration, tolerability, cost, availability, long-term treatment plans, and the patient's individual goals all matter.

What Happens When GLP-1 Treatment Is Stopped?

One of the most important questions about GLP-1 therapy is what happens after treatment ends. These medicines influence biological pathways that continue to regulate appetite and energy balance, so stopping treatment does not necessarily mean that the physiological effects will remain permanently. Some patients may experience increased hunger or regain some of the weight they previously lost after discontinuing therapy. This is one reason obesity is increasingly approached as a chronic disease rather than as a short-term problem that can always be solved with a temporary intervention. NIDDK notes that prescription weight-management medications can help with weight loss and maintenance while being used as part of a lifestyle program, and its professional commentary also highlights questions around treatment discontinuation and long-term benefit. The appropriate duration of treatment is therefore a clinical decision rather than a fixed rule such as “use it for three months and stop.” Patients should discuss treatment goals, maintenance strategies, lifestyle support, adverse effects, and alternative options with their healthcare professional before discontinuing therapy.

Approved Medicines vs. Compounded GLP-1 Products

The rapid demand for GLP-1 medicines has also created a growing market for compounded semaglutide and tirzepatide products, but approved and compounded medicines should not automatically be treated as equivalent. The FDA states that compounded drugs are not FDA-approved and do not undergo the agency's premarket review for safety, effectiveness, and quality. The agency has reported dosing errors associated with compounded injectable semaglutide, partly because compounded products may have different concentrations and may use measurement systems that confuse patients or healthcare professionals. As of May 31, 2026, the FDA reported receiving 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, while also cautioning that adverse-event reports cannot always establish that the medicine itself directly caused the event. In March 2026, the FDA also announced warning letters to 30 telehealth companies concerning allegedly false or misleading marketing of compounded GLP-1 products. Patients should therefore obtain prescription medicines through legitimate channels and discuss any compounded product with a qualified healthcare professional.

Frequently Asked Questions

1. Are GLP-1 medications only for diabetes?

No. Some GLP-1-related medicines are approved for chronic weight management in eligible people with overweight or obesity, while other products and doses are approved for type 2 diabetes. Tirzepatide, a dual GIP/GLP-1 receptor agonist, also has additional approved uses in the United States, including treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. The exact indication depends on the product, formulation, dose, country, and regulatory approval. A medicine prescribed for diabetes should not automatically be assumed to be appropriate for weight management at the same dose or schedule.

2. How quickly do GLP-1 medications cause weight loss?

The response varies from person to person, and weight loss generally develops over weeks and months rather than overnight. Many injectable products use dose escalation, so the full therapeutic dose may not be reached immediately. Clinical trials report averages across groups, but those averages cannot predict exactly how much weight one individual will lose. NIDDK notes that weight-management medication works best as part of a broader program involving healthy eating and physical activity.

3. What are the most common side effects of GLP-1 medicines?

Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite are among the most commonly encountered effects. Gastrointestinal adverse effects are particularly common during dose escalation. In the SURMOUNT-1 tirzepatide trial, gastrointestinal adverse events were the most common adverse events and were generally mild to moderate. Severe or persistent symptoms should be discussed promptly with a healthcare professional.

4. Can GLP-1 medicines be used with other diabetes medicines?

They can be combined with other diabetes medicines in appropriate patients, but the combination should be supervised. The risk of hypoglycemia can increase when a GLP-1 medicine is used with insulin or certain insulin secretagogues. Medication doses may therefore need adjustment based on glucose readings, HbA1c, symptoms, and the overall treatment plan.

5. Are compounded GLP-1 medications the same as FDA-approved products?

A compounded medicine should not automatically be considered equivalent to an FDA-approved product. The FDA states that compounded drugs are not FDA-approved and do not undergo the same premarket review for safety, effectiveness, and quality. The agency has also reported dosing errors and adverse events involving compounded semaglutide and has warned about misleading marketing claims surrounding compounded GLP-1 products.

Conclusion

GLP-1 medications represent an important development in the treatment of type 2 diabetes, obesity, and related cardiometabolic conditions. Their effects go far beyond simply lowering blood glucose: they interact with hormone pathways that influence insulin secretion, glucagon regulation, gastric emptying, appetite, food intake, and body weight. Semaglutide and liraglutide are GLP-1 receptor agonists, while tirzepatide acts on both GIP and GLP-1 receptors, giving the newer class of incretin-based therapies an increasingly important role in metabolic medicine. Clinical trials have demonstrated substantial weight loss with agents such as semaglutide and tirzepatide, and semaglutide has also demonstrated cardiovascular benefit in a specific population of adults with cardiovascular disease and overweight or obesity. At the same time, these medicines are not risk-free, and gastrointestinal adverse effects, contraindications, drug interactions, hypoglycemia with certain combinations, and medication-quality concerns all deserve attention. The safest approach is to view GLP-1 therapy as a medical treatment rather than a quick-fix weight-loss trend, with the specific medicine, dose, duration, and monitoring plan selected according to the patient's health status and treatment goals. FDA information also makes clear that patients should be cautious with unapproved or improperly marketed compounded products, particularly when dosing instructions or product concentrations are unclear.

References : 

 1. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F,  Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019 Dec;30:72-130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. PMID: 31767182; PMCID: PMC6812410.

2. Tudosie AC, Marin LM, Popa SG, Golli AL. Glucagon-like Peptide-1 and Dual GIP/GLP-1 Receptor Agonists in Brain: Exploring the Expanding Role and Safety in Neuropsychiatry. Int J Mol Sci. 2026 Apr 18;27(8):3628. doi: 10.3390/ijms27083628. PMID: 42074266; PMCID: PMC13115786.